Abstract
The combination of lomustine and bevacizumab is a commonly used salvage treatment for recurrent glioblastoma (GBM). We investigated the toxicity and efficacy of lomustine plus bevacizumab (lom-bev) in a community-based patient cohort and made a comparison to another frequently used combination therapy consisting of irinotecan plus bevacizumab (iri-bev). Seventy patients with recurrent GBM were treated with lomustine 90 mg/m2 every 6 weeks and bevacizumab 10 mg/kg every 2 weeks. Toxicity was registered and compared to the toxicity observed in 219 recurrent GBM patients who had previously been treated with irinotecan 125 mg/m2 and bevacizumab 10 mg/kg every 2 weeks. The response rate was 37.1% for lom-bev and 30.1% for iri-bev. Median progression-free survival (PFS) was 23 weeks for lom-bev and 21 weeks for iri-bev (p = 0.9). Overall survival (OS) was 37 weeks for lom-bev and 32 weeks for iri-bev (p = 0.5). Lom-bev caused a significantly higher frequency of thrombocytopenia (11.4% grade 3–4) compared to iri-bev (3.5% grade 3–4). Iri-bev patients had more gastrointestinal toxicity with regard to nausea, vomiting, diarrhea, constipation and stomatitis. Within the limitations of the study lom-bev is a well-tolerated treatment for recurrent GBM, although hematological toxicity may be a dose limiting factor. No significant differences between lom-bev and iri-bev were observed with regard to PFS or OS. The differences in toxicity profiles between lom-bev and iri-bev could guide treatment decision in recurrent GBM therapy as efficacy is equal and no predictive factors for efficacy exist.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Stupp R, Weber DC (2005) The role of radio- and chemo-therapy in glioblastoma. Onkologie 28(6–7):315–317
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996
Jakobsen JN, Hasselbalch B, Stockhausen MT, Lassen U, Poulsen HS (2011) Irinotecan and bevacizumab in recurrent glioblastoma multiforme. Expert Opin Pharmacother 12(5):825–833
Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC et al (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15(9):943–953
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963–1972
Poulsen HS, Grunnet K, Sorensen M, Olsen P, Hasselbalch B, Nelausen K et al (2009) Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol 48(1):52–58
Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277–1280
Urup T, Dahlrot RH, Grunnet K, Christensen IJ, Michaelsen SR, Toft A et al (2016) Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan. Acta Oncol 55(4):418–422
Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733–4740
Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I et al (2017) Lomustine and Bevacizumab in Progressive Glioblastoma. N Engl J Med 377(20):1954–1963
Huang RY, Rahman R, Ballman KV, Felten SJ, Anderson SK, Ellingson BM et al (2016) The impact of T2/FLAIR evaluation per RANO criteria on response assessment of recurrent glioblastoma patients treated with bevacizumab. Clin Cancer Res 22(3):575–5881
Moller S, Grunnet K, Hansen S, Schultz H, Holmberg M, Sorensen M et al (2012) A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy. Acta Oncol 51(6):797–804
Henriksson R, Asklund T, Poulsen HS (2011) Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neuro Oncol 104(3):639–646
Tabouret E, Boudouresque F, Barrie M, Matta M, Boucard C, Loundou A et al (2014) Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. Neuro Oncol 16(3):392–399
Urup T, Michaelsen SR, Olsen LR, Toft A, Christensen IJ, Grunnet K et al (2016) Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients. Mol Oncol 10(8):1160–1168
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no conflict of interest.
Ethical approval
This study was performed according to the Declaration of Helsinki and Danish legislation and permissions was given from the Danish Data Protection Agency (2015-41-4118).
Informed consent
All patients gave informed consent.
Additional information
J. N. Jakobsen and T. Urup are first co-authors contributed equally to the study.
Rights and permissions
About this article
Cite this article
Jakobsen, J.N., Urup, T., Grunnet, K. et al. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients. J Neurooncol 137, 439–446 (2018). https://doi.org/10.1007/s11060-017-2736-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-017-2736-x